JP4322675B2 - ムスカリン受容体アンタゴニストとしてのアミノテトラリン誘導体 - Google Patents
ムスカリン受容体アンタゴニストとしてのアミノテトラリン誘導体 Download PDFInfo
- Publication number
- JP4322675B2 JP4322675B2 JP2003549317A JP2003549317A JP4322675B2 JP 4322675 B2 JP4322675 B2 JP 4322675B2 JP 2003549317 A JP2003549317 A JP 2003549317A JP 2003549317 A JP2003549317 A JP 2003549317A JP 4322675 B2 JP4322675 B2 JP 4322675B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- compound
- formula
- halogen
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33667501P | 2001-12-03 | 2001-12-03 | |
| PCT/EP2002/013219 WO2003048125A1 (en) | 2001-12-03 | 2002-11-25 | Aminotetralin derivatives as muscarinic receptor antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005518368A JP2005518368A (ja) | 2005-06-23 |
| JP2005518368A5 JP2005518368A5 (https=) | 2005-12-22 |
| JP4322675B2 true JP4322675B2 (ja) | 2009-09-02 |
Family
ID=23317154
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003549317A Expired - Fee Related JP4322675B2 (ja) | 2001-12-03 | 2002-11-25 | ムスカリン受容体アンタゴニストとしてのアミノテトラリン誘導体 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US6635658B2 (https=) |
| EP (1) | EP1453806B1 (https=) |
| JP (1) | JP4322675B2 (https=) |
| KR (1) | KR100668231B1 (https=) |
| CN (1) | CN100358870C (https=) |
| AR (1) | AR037611A1 (https=) |
| AT (1) | ATE381541T1 (https=) |
| AU (1) | AU2002352124A1 (https=) |
| BR (1) | BR0214649A (https=) |
| CA (1) | CA2469055C (https=) |
| DE (1) | DE60224221T2 (https=) |
| ES (1) | ES2297029T3 (https=) |
| MX (1) | MXPA04005313A (https=) |
| PL (1) | PL370799A1 (https=) |
| RU (1) | RU2311408C2 (https=) |
| WO (1) | WO2003048125A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA04005313A (es) * | 2001-12-03 | 2004-09-13 | Hoffmann La Roche | Derivados de aminotetralin como antagonistas del receptor muscarinico. |
| AU2002345266B2 (en) | 2002-07-08 | 2009-07-02 | Ranbaxy Laboratories Limited | 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists |
| US7488748B2 (en) * | 2003-01-28 | 2009-02-10 | Ranbaxy Laboratories Limited | 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists |
| WO2004089898A1 (en) | 2003-04-09 | 2004-10-21 | Ranbaxy Laboratories Limited | Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists |
| EA009387B1 (ru) | 2003-04-11 | 2007-12-28 | Рэнбакси Лабораториз Лимитед | Азабициклические производные в качестве антагонистов мускаринового рецептора |
| WO2006008119A1 (en) | 2004-07-16 | 2006-01-26 | Proteosys Ag | Muscarinic antagonists with parp and sir modulatng activity as agents for inflammatory diseases |
| EP1797040A1 (en) * | 2004-09-29 | 2007-06-20 | Ranbaxy Laboratories Limited | Muscarinic receptor antagonists |
| WO2006054162A1 (en) * | 2004-11-19 | 2006-05-26 | Ranbaxy Laboratories Limited | Azabicyclic muscarinic receptor antagonists |
| WO2006064304A1 (en) * | 2004-12-15 | 2006-06-22 | Ranbaxy Laboratories Limited | Acid addition salts of muscarinic receptor antagonists |
| US9198897B2 (en) * | 2005-01-19 | 2015-12-01 | Neurohealing Pharmaceuticals, Inc. | Methods and compositions for decreasing saliva production |
| AU2006239929B2 (en) * | 2005-04-22 | 2011-11-03 | Alantos Pharmaceuticals Holding, Inc. | Dipeptidyl peptidase-IV inhibitors |
| EP1888525A1 (en) * | 2005-05-03 | 2008-02-20 | Ranbaxy Laboratories Limited | 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives as muscarinic receptor antagonists |
| WO2010081825A2 (en) | 2009-01-13 | 2010-07-22 | Proteosys Ag | Pirenzepine as an agent in cancer treatment |
| NZ723198A (en) * | 2012-11-20 | 2018-11-30 | Boehringer Ingelheim Animal Health Usa Inc | Anthelmintic compounds and compositions and methods of using thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3718317A1 (de) * | 1986-12-10 | 1988-06-16 | Bayer Ag | Substituierte basische 2-aminotetraline |
| CA1331191C (en) | 1988-03-25 | 1994-08-02 | Bengt Ronny Andersson | Therapeutically useful tetralin derivatives |
| FR2659323B1 (fr) | 1990-03-07 | 1992-06-12 | Synthelabo | Derives de 4-(aminomethyl) piperidine, leur preparation et leur application en therapeutique. |
| FR2659853A1 (fr) | 1990-03-22 | 1991-09-27 | Midy Spa | Utilisation de derives 2-aminotetraliniques pour la preparation de medicaments destines a combattre les troubles de la motricite intestinale. |
| MY110227A (en) * | 1991-08-12 | 1998-03-31 | Ciba Geigy Ag | 1-acylpiperindine compounds. |
| CA2258044C (en) * | 1996-07-01 | 2007-09-04 | Schering Corporation | Muscarinic antagonists |
| EP0912515B1 (en) * | 1996-07-10 | 2002-11-13 | Schering Corporation | 1,4-di-substituted piperidines as muscarinic antagonists |
| US6319920B1 (en) * | 1998-02-27 | 2001-11-20 | Syntex (U.S.A.) Llc | 2-arylethyl-(piperidin-4-ylmethyl)amine derivatives |
| PL204753B1 (pl) | 2000-05-25 | 2010-02-26 | Hoffmann La Roche | Podstawiony 1-aminoalkilolaktam , zawierający go środek farmaceutyczny, sposób wytwarzania podstawionego 1-aminoalkilolaktamu i jego zastosowanie |
| WO2001090082A1 (en) * | 2000-05-25 | 2001-11-29 | F. Hoffmann-La Roche Ag | Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists |
| MXPA04005313A (es) * | 2001-12-03 | 2004-09-13 | Hoffmann La Roche | Derivados de aminotetralin como antagonistas del receptor muscarinico. |
-
2002
- 2002-11-25 MX MXPA04005313A patent/MXPA04005313A/es active IP Right Grant
- 2002-11-25 RU RU2004120558/04A patent/RU2311408C2/ru not_active IP Right Cessation
- 2002-11-25 KR KR1020047008423A patent/KR100668231B1/ko not_active Expired - Fee Related
- 2002-11-25 ES ES02787797T patent/ES2297029T3/es not_active Expired - Lifetime
- 2002-11-25 DE DE60224221T patent/DE60224221T2/de not_active Expired - Lifetime
- 2002-11-25 PL PL02370799A patent/PL370799A1/xx not_active Application Discontinuation
- 2002-11-25 CN CNB028240170A patent/CN100358870C/zh not_active Expired - Fee Related
- 2002-11-25 BR BR0214649-5A patent/BR0214649A/pt not_active IP Right Cessation
- 2002-11-25 CA CA2469055A patent/CA2469055C/en not_active Expired - Fee Related
- 2002-11-25 EP EP02787797A patent/EP1453806B1/en not_active Expired - Lifetime
- 2002-11-25 JP JP2003549317A patent/JP4322675B2/ja not_active Expired - Fee Related
- 2002-11-25 AU AU2002352124A patent/AU2002352124A1/en not_active Abandoned
- 2002-11-25 WO PCT/EP2002/013219 patent/WO2003048125A1/en not_active Ceased
- 2002-11-25 AT AT02787797T patent/ATE381541T1/de not_active IP Right Cessation
- 2002-12-02 US US10/308,092 patent/US6635658B2/en not_active Expired - Fee Related
- 2002-12-02 AR ARP020104638A patent/AR037611A1/es not_active Application Discontinuation
-
2003
- 2003-06-27 US US10/608,604 patent/US6806278B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| ES2297029T3 (es) | 2008-05-01 |
| DE60224221D1 (de) | 2008-01-31 |
| CN1639124A (zh) | 2005-07-13 |
| ATE381541T1 (de) | 2008-01-15 |
| US20040092604A1 (en) | 2004-05-13 |
| CN100358870C (zh) | 2008-01-02 |
| EP1453806B1 (en) | 2007-12-19 |
| US6635658B2 (en) | 2003-10-21 |
| AR037611A1 (es) | 2004-11-17 |
| JP2005518368A (ja) | 2005-06-23 |
| AU2002352124A1 (en) | 2003-06-17 |
| MXPA04005313A (es) | 2004-09-13 |
| US6806278B2 (en) | 2004-10-19 |
| EP1453806A1 (en) | 2004-09-08 |
| KR20050044641A (ko) | 2005-05-12 |
| BR0214649A (pt) | 2004-11-03 |
| KR100668231B1 (ko) | 2007-01-16 |
| US20030171362A1 (en) | 2003-09-11 |
| CA2469055C (en) | 2011-03-29 |
| RU2004120558A (ru) | 2005-07-20 |
| RU2311408C2 (ru) | 2007-11-27 |
| PL370799A1 (en) | 2005-05-30 |
| DE60224221T2 (de) | 2008-12-11 |
| CA2469055A1 (en) | 2003-06-12 |
| WO2003048125A1 (en) | 2003-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6645958B2 (en) | Benzocycloalkylenylamine derivatives as muscarinic receptor antagonists | |
| JP4322675B2 (ja) | ムスカリン受容体アンタゴニストとしてのアミノテトラリン誘導体 | |
| AU2001260310A1 (en) | Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists | |
| JP4353803B2 (ja) | ムスカリン受容体アンタゴニストとしての４−ピペリジニルアルキルアミン誘導体 | |
| CA2420177C (en) | Quinazoline derivatives as alpha-1 adrenergic antagonists | |
| CN101384260A (zh) | 哌嗪衍生物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080513 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080731 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20081118 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090209 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090217 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090313 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090602 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090603 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120612 Year of fee payment: 3 |
|
| LAPS | Cancellation because of no payment of annual fees |